114 related articles for article (PubMed ID: 17065016)
1. Severe neuropathy in a patient with Waldenstrom disease: from a challenging diagnosis to clinical improvement by innovative therapy.
Bertazzoni P; Andreola G; Laszlo D; Agazzi A; Bassi S; Gigli F; Martinelli G
Leuk Lymphoma; 2006 Sep; 47(9):1970-2. PubMed ID: 17065016
[No Abstract] [Full Text] [Related]
2. Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia.
Lazarevic VLj; Liljeholm M; Forsberg K; Söderberg S; Wahlin A
Leuk Lymphoma; 2008 Jun; 49(6):1209-11. PubMed ID: 18452089
[No Abstract] [Full Text] [Related]
3. Cryoglobulinaemia identified by repeated analytical failure of laboratory tests.
Hira-Kazal R; Sayar Z; Kothari J; Ayrton P; Berney S; Maher J
Lancet; 2014 Jan; 383(9914):382. PubMed ID: 24461124
[No Abstract] [Full Text] [Related]
4. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
5. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Mancuso P; Pruneri G; Radice D; Pinto A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
J Clin Oncol; 2010 May; 28(13):2233-8. PubMed ID: 20368573
[TBL] [Abstract][Full Text] [Related]
6. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström's macroglobulinemia.
Alfaraj WA; Cachia D; Tummala S; Thomas SK; Manasanch EE
Ann Hematol; 2016 Jan; 95(2):347-8. PubMed ID: 26432713
[No Abstract] [Full Text] [Related]
7. Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.
Pilorge S; Park S; Dreyfus F; Bouscary D; Tamburini J
Leuk Lymphoma; 2010 Dec; 51(12):2288-90. PubMed ID: 20929331
[No Abstract] [Full Text] [Related]
8. Waldenström macroglobulinemia of the orbit.
Ranchod TM; Mansour TN; Fogt F; Gausas RE
Ophthalmic Plast Reconstr Surg; 2008; 24(1):76-7. PubMed ID: 18209658
[TBL] [Abstract][Full Text] [Related]
9. Waldenström macroglobulinaemia and intestinal lymphangiectasia.
Cooke RE; Kalnins RM; Ho WK
Br J Haematol; 2014 Nov; 167(3):292. PubMed ID: 25039993
[No Abstract] [Full Text] [Related]
10. Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.
Weiss L; Melchardt T; Neureiter D; Kemmerling R; Moshir S; Pleyer L; Greil R; Egle A
J Clin Oncol; 2011 Aug; 29(24):e696-8. PubMed ID: 21730268
[No Abstract] [Full Text] [Related]
11. Waldenström macroglobulinemia: my way.
Gertz M
Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide and rituximab in Waldenstrom macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Briccetti FM; Pasmantier M; Zimbler H; Cooper RB; Moore M; Hill J; Rauch A; Garbo L; Chu L; Chua C; Nantel SH; Lovett DR; Boedeker H; Sonneborn H; Howard J; Musto P; Ciccarelli BT; Hatjiharissi E; Anderson KC
Blood; 2008 Dec; 112(12):4452-7. PubMed ID: 18713945
[TBL] [Abstract][Full Text] [Related]
13. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia.
Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Pinto A; Negri M; Martinelli G
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):130-2. PubMed ID: 21454213
[TBL] [Abstract][Full Text] [Related]
14. Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia.
Forconi F; Toraldo F; Sozzi E; Amato T; Raspadori D; Lauria F
Leuk Lymphoma; 2007 Dec; 48(12):2441-3. PubMed ID: 18067021
[No Abstract] [Full Text] [Related]
15. Resolution of Waldenström's macroglubulinemia related isolated neutropenia by immunochemotherapy.
van Gelder M; van Marion A; Goossens V; Bommer M; Leblond V
Am J Hematol; 2011 Apr; 86(4):380-2. PubMed ID: 21442645
[No Abstract] [Full Text] [Related]
16. Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.
Hivert B; Tamburini J; Vekhoff A; Tournilhac O; Leblond V; Morel P
Haematologica; 2011 May; 96(5):785-8. PubMed ID: 21393333
[No Abstract] [Full Text] [Related]
17. Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
Rabascio C; Laszlo D; Andreola G; Saronni L; Radice D; Rigacci L; Fabbri A; Frigeri F; Calabrese L; Billio A; Bertolini F; Martinelli G
Leuk Res; 2010 Apr; 34(4):454-7. PubMed ID: 19647871
[TBL] [Abstract][Full Text] [Related]
18. Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
Peinert S; Seymour JF
Leuk Lymphoma; 2010 Oct; 51(10):1767-70. PubMed ID: 20919859
[No Abstract] [Full Text] [Related]
19. The efficacy and stem cell toxicity of cladribine and rituximab in the treatment of patients with chronic lymphocytic leukemia: are all purine analogs created equal?
Tadmor T; Polliack A; Tam CS
Leuk Lymphoma; 2010 Apr; 51(4):571-3. PubMed ID: 20141447
[No Abstract] [Full Text] [Related]
20. Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab.
Gironi M; Saresella M; Ceresa L; Calvo M; Ferrante P; Merli F; Nemni R
Haematologica; 2006 Jun; 91(6 Suppl):ECR17. PubMed ID: 16785123
[No Abstract] [Full Text] [Related]
[Next] [New Search]
